4 Reasons JPMorgan Just Downgraded Merrimack Pharmaceuticals
October 07, 2016 at 13:30 PM EDT
JPMorgan has downgraded Merrimack Pharmaceuticals Inc (NASDAQ: MACK) to Neutral from Overweight and cut the price target to $7 from $8, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.